Bathi saben saham sajrone rolas wulan pungkasan: Serina Therapeutics Inc (SER)

The growth of Serina Therapeutics, Inc. (SER) is based on the validation of extended-release delivery systems for Parkinson's disease drugs and patent protection. The current trailing 12-month EPS helps filter out market noise, with -1.76 serving as the current metric level. Serina Therapeutics, Inc. (SER) develops brain therapies through partnerships with scientific centers, relying on strict FDA standards and capital inflows from Big Pharma.
Rincian analitis lan laporan data perusahaan Serina (SER)

Fundamental analysis requires an assessment of the actual yield of each security. This indicator measures the total annual net income divided by the total number of shares outstanding. By analyzing the 12-month net income per share chart, an investor determines the efficiency of the business capitalization. For Serina Therapeutics, Inc. (SER), this metric confirms financial stability while optimizing polymer supply chains. The diversification of laboratories minimizes operational risks, directly impacting the final profitability.